Tesamorelin Ipamorelin Blend Dosage: What Research Actually Reports
Tesamorelin and ipamorelin are often packed in one vial because one is a growth hormone-releasing hormone (GHRH) analog and the other is a ghrelin-receptor agonist. They do not share a dose, a half-life, or a pivotal trial. This page separates the figures that exist for each compound from the ratio printed on a mixed research vial. It is a laboratory reference only, not dosing advice, and these compounds are not for human consumption.
Two receptors, two dose scales
Tesamorelin is a 44-amino-acid analog of GHRH. In the phase 3 trials in HIV-associated lipodystrophy it was given at 2 mg subcutaneously once daily. A later formulation is labeled at 1.4 mg once daily for that same narrow indication. Research summaries on this site use a 1 to 2 mg once-daily band. The single-compound numbers are on the tesamorelin dosage chart.
Ipamorelin is a pentapeptide of about 712 daltons. It binds the ghrelin receptor and is discussed for a short growth hormone pulse with little effect on cortisol or prolactin compared with earlier secretagogues. Its research half-life is about two hours, so protocols repeat it. The ipamorelin protocol lists 100 to 300 mcg per administration, two or three times daily, away from food. That is a microgram scale. Dissolving both peptides together does not turn milligrams of tesamorelin into micrograms of ipamorelin.
A GHRH signal plus a ghrelin-receptor signal can produce a larger growth hormone pulse than either pathway alone. That pattern was mapped with CJC-1295 and modified GRF 1-29, not with a fixed tesamorelin-ipamorelin product. See the CJC-1295 and ipamorelin dosage guide. Tesamorelin is a different molecule, so those doses do not transfer. The tesamorelin versus CJC-1295 note explains the gap.
Research-reported figures, not a blend prescription
Each row below is a figure reported for one compound on its own. Adding a tesamorelin row to an ipamorelin row does not create a studied blend dose. No controlled trial has set a combined amount, a ratio, or a cycle length for this pair.
| Compound | Setting | Reported amount | Schedule in that setting |
|---|---|---|---|
| Tesamorelin | HIV lipodystrophy phase 3 trials | 2 mg subcutaneous | Once daily |
| Tesamorelin | Later SV product label | 1.4 mg subcutaneous | Once daily |
| Tesamorelin | Research protocol summaries | 1 to 2 mg | Once daily, often in the evening |
| Ipamorelin | Research protocols | 100 to 300 mcg | 2 to 3 times daily, fasted |
| Ipamorelin | Common single research pulse | 200 to 300 mcg | Pre-sleep or another fasted window |
| Blend of both | Controlled combination trial | None identified | No established blend dose |
Figures above are research-reported or label-reported, not dosing advice and not an instruction to administer either peptide.
One injection cannot copy both schedules
Tesamorelin's studied pattern is one daily injection. Ipamorelin's short half-life is why research protocols split it across a fasted day, because insulin blunts growth hormone release. One pre-mixed draw can match the tesamorelin clock or a single ipamorelin pulse. It cannot reproduce both a multi-dose ipamorelin day and a full 1 to 2 mg tesamorelin amount unless the ratio lands on both, and most fixed blends do not.
A supplier freezes that ratio. A vial marked only as a "10 mg blend" might be mostly one peptide, or a split never stated in milligrams of each. Until the label lists both masses, there is no way to know whether one draw is near 2 mg plus 200 mcg. Why the pair is discussed at all is in the tesamorelin and ipamorelin overview. Handling notes for related compounds sit in the protocol library.
Worked reconstitution math
Separate vials are the only way to record each peptide on its own scale. The dosage calculator converts vial mass and diluent volume into syringe units. The examples below are arithmetic for checking a label. They are not use instructions.
Ipamorelin, using the protocol dilution: a 5 mg vial plus 2 ml of bacteriostatic water is 2,500 mcg per ml. A 200 mcg amount is 0.08 ml, or 8 units on a U-100 insulin syringe. A 300 mcg amount is 0.12 ml, or 12 units.
Tesamorelin: a 10 mg vial plus 2 ml is 5 mg per ml. A 2 mg amount is 0.4 ml. A 1.4 mg amount is 0.28 ml. A 1 mg amount is 0.2 ml.
A fixed ratio changes the result. Suppose a label reads 5 mg tesamorelin and 5 mg ipamorelin in 2 ml. Each peptide is then 2.5 mg per ml. A 0.08 ml draw holds 200 mcg of each: a typical ipamorelin pulse, and far below 1 to 2 mg of tesamorelin. Drawing 0.8 ml to reach 2 mg of tesamorelin also delivers 2 mg of ipamorelin, several times the 100 to 300 mcg research pulse. The ratio, not the syringe, is the constraint.
What the evidence does not cover
No randomized trial has defined a tesamorelin-ipamorelin blend dose, duration, or cycling pattern. Ipamorelin has no approved human indication. Tesamorelin's approval is limited to excess abdominal fat in HIV-associated lipodystrophy, at the labeled daily amount. Signals discussed around these secretagogues include IGF-1 elevation, glucose changes, injection-site reactions, and fluid retention. Read them on the tesamorelin side effects page and the ipamorelin research overview.
Purity is the other variable. A blend certificate of analysis should name both sequences and both masses. A single purity percentage on a mixed vial does not reveal the ratio. Tested material is listed on the supplier list.